Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 10/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ESRRG | P62508 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257347 | 0.83 | EPHX2 (0.59) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL5177664 | 0.83 | EPHX2 (0.68) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL12993420 | 0.78 | RAB9A (0.88) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL19898106 | 0.78 | EPHX2 (0.59) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL4618832 | 0.77 | EPHX2 (0.68) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL3278159 | 0.76 | LMNA (0.68) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL3420620 | 0.76 | EPHX2 (0.65) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL5175710 | 0.75 | CA1 (0.69) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL7113776 | 0.75 | RAB9A (1.00) | LMNARAB9AEPHX2NR1H4HDAC3 | |
| SCHEMBL19928752 | 0.75 | CYP1A2 (0.49) | LMNARAB9AEPHX2NR1H4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1984340-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | LMNA 1337/4885RAB9A 1226/4885EPHX2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.